ES2107622T3 - Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal. - Google Patents

Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal.

Info

Publication number
ES2107622T3
ES2107622T3 ES93303863T ES93303863T ES2107622T3 ES 2107622 T3 ES2107622 T3 ES 2107622T3 ES 93303863 T ES93303863 T ES 93303863T ES 93303863 T ES93303863 T ES 93303863T ES 2107622 T3 ES2107622 T3 ES 2107622T3
Authority
ES
Spain
Prior art keywords
treatment
medication
vaginal dryness
vulvar dystrophy
vulvar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93303863T
Other languages
English (en)
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2107622T3 publication Critical patent/ES2107622T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

UN ACIDO GAMMA-LINOLENICO (GLA) Y/O DIHOMO-GAMMA-LINOLENICO (DGLA) PUEDE SER USADO EN EL TRATAMIENTO DE DISTROFIA VULVA Y/O SEQUEDAD VAGINAL. OTROS ACIDOS GRASOS ESENCIALES DE LAS SERIES N-6 O N-3 PUEDEN TAMBIEN SER USADOS EN ASOCIACION CON GLA Y/O DGLA.
ES93303863T 1992-05-27 1993-05-19 Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal. Expired - Lifetime ES2107622T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929211229A GB9211229D0 (en) 1992-05-27 1992-05-27 Fatty acid treatment

Publications (1)

Publication Number Publication Date
ES2107622T3 true ES2107622T3 (es) 1997-12-01

Family

ID=10716100

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93303863T Expired - Lifetime ES2107622T3 (es) 1992-05-27 1993-05-19 Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal.

Country Status (15)

Country Link
US (1) US5380757A (es)
EP (1) EP0572159B1 (es)
JP (1) JPH0640903A (es)
AT (1) ATE156015T1 (es)
AU (1) AU660223B2 (es)
CA (1) CA2096556A1 (es)
DE (1) DE69312579T2 (es)
DK (1) DK0572159T3 (es)
ES (1) ES2107622T3 (es)
GB (1) GB9211229D0 (es)
GR (1) GR3025178T3 (es)
NO (1) NO931923L (es)
NZ (1) NZ247660A (es)
TW (1) TW336171B (es)
ZA (1) ZA933469B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707850A1 (en) * 1994-09-21 1996-04-24 Scotia Holdings Plc Use of polyunsaturated fatty acids for the manufacture of a medicament for the treatment of brest pain
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
AU2001261244B2 (en) * 2000-05-09 2006-08-03 Nitromed, Inc. Infrared thermography and methods of use
ATE369868T1 (de) * 2000-06-27 2007-09-15 Qualilife Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung der weiblichen sexuellen reaktion
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US20030236284A1 (en) * 2002-06-14 2003-12-25 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
EP1883401B1 (en) * 2005-01-20 2015-11-11 Kayban Pty Ltd. Anti-microbial agent
WO2009058799A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US20110159074A1 (en) * 2009-12-30 2011-06-30 Raphael Warren Wipe Article Comprising Lotion Composition Comprising Omega-6 Fatty Acid And Method Of Improving Skin Barrier Function
CA2784031A1 (en) * 2009-12-30 2011-07-07 The Procter & Gamble Company Absorbent article comprising lotion composition comprising omega-6 fatty acid
US20120083747A1 (en) * 2010-10-01 2012-04-05 Leo Galland Vaginal renewal complex and applicator
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145686A (en) * 1982-02-03 1992-09-08 Efamol Limited Topical pharmaceutical compositions
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments

Also Published As

Publication number Publication date
TW336171B (en) 1998-07-11
ZA933469B (en) 1994-09-26
AU660223B2 (en) 1995-06-15
US5380757A (en) 1995-01-10
EP0572159A1 (en) 1993-12-01
AU3861193A (en) 1993-12-02
DE69312579T2 (de) 1998-03-05
ATE156015T1 (de) 1997-08-15
GB9211229D0 (en) 1992-07-08
GR3025178T3 (en) 1998-02-27
DE69312579D1 (de) 1997-09-04
CA2096556A1 (en) 1993-11-28
NO931923L (no) 1993-11-29
EP0572159B1 (en) 1997-07-30
JPH0640903A (ja) 1994-02-15
NZ247660A (en) 1997-06-24
NO931923D0 (no) 1993-05-26
DK0572159T3 (da) 1998-03-09

Similar Documents

Publication Publication Date Title
NO931923L (no) Fettsyre-behandling
ATE96313T1 (de) Fettsaeure-zusammensetzungen.
SE8902701D0 (sv) Fettsyrakomposition
ES2045120T4 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
GR3006068T3 (es)
EP0307128A3 (en) Azithromycin and derivatives as antiprotozoal agents
DE3366530D1 (en) Pharmaceutical composition
ATE22532T1 (de) Pharmazeutische zusammensetzung.
DE3485337D1 (de) Topische zubereitungen mit gehalt an teer und fettsaeuren.
ATE19855T1 (de) Pharmazeutische und diaetetische zusammensetzung.
TW223589B (es)
GB9412925D0 (en) Combination of aldose reductase inhibitors with gamma-linolenic (GLA) dihomogammalinolenic (DGLA) or arachidonic (AA) acids in the treatment of diabetic

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 572159

Country of ref document: ES